Skip to content
DataLookout
Menu

NCT04641143

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 80 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 6 words
    • Primary endpoint revised
    • Secondary endpoints revised (3)
    • Site details revised at 2 of 73 sites
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 700 to confirmed 456
    • Primary and study completion dates changed from estimate of Nov 2025 to Oct 27, 2025
    v79
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 96 to 73
    • Primary and study completion dates: Jun 2025 to Nov 2025
    v78
  4. Minor Site details revised at 1 of 96 sitesv77
  5. Minor Site details revised at 2 of 96 sitesv76
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Site details revised at 1 of 96 sitesv75
  2. Minor Site details revised at 21 of 96 sitesv74
  3. Minor Site details revised at 1 of 96 sitesv73
  4. Minor Site details revised at 17 of 96 sitesv72
  5. Minor Site details revised at 1 of 96 sitesv71
  6. Minor Site details revised at 1 of 96 sitesv70
  7. Minor Study sites: 95 to 96v69
  8. Minor Study sites: 85 to 95v68
  9. Minor Primary and study completion dates: Dec 2024 to Jun 2025v67
  10. Minor Primary and study completion dates: Jun 30, 2024 to Dec 2024v66
  11. Minor Site details revised at 1 of 85 sitesv65
  12. Minor Site details revised at 21 of 85 sitesv64
  13. Notable Primary and study completion dates: Dec 15, 2023 to Jun 30, 2024v63
  14. Notable Primary and study completion dates: Mar 17, 2023 to Dec 15, 2023v62
  15. Minor Site details revised at 1 of 85 sitesv61
  16. Minor Enrollment target: 600 to 700
    • Study sites: 92 to 85
    v59
  17. Minor Site contacts updated at 2 of 92 sitesv58
  18. Minor Site contacts updated at 1 of 92 sitesv57
  19. Minor Site contacts updated at 1 of 92 sitesv56
  20. Notable Eligibility criteria shortened, about 12 wordsv55
  21. Minor Site details revised at 1 of 92 sitesv54
  22. Minor Site details revised at 1 of 92 sitesv53
  23. Minor Site details revised at 1 of 92 sitesv52
  24. Minor Site details revised at 1 of 92 sitesv51
  25. Minor Site details revised at 1 of 92 sitesv50
  26. Minor Site details revised at 1 of 92 sitesv49
  27. Minor Site details revised at 1 of 92 sitesv48
  28. Minor Study sites: 91 to 92v47
  29. Minor Site details revised at 2 of 91 sitesv46
  30. Minor Site details revised at 1 of 91 sitesv45
  31. Minor Site details revised at 1 of 91 sitesv44
  32. Minor Site details revised at 1 of 91 sitesv43
  33. Minor Site details revised at 1 of 91 sitesv42
  34. Minor Site details revised at 1 of 91 sitesv41
  35. Minor Site details revised at 1 of 91 sitesv40
  36. Minor Site details revised at 1 of 91 sitesv39
  37. Minor Site details revised at 1 of 91 sitesv38
  38. Minor Site details revised at 1 of 91 sitesv37
  39. Minor Site details revised at 1 of 91 sitesv36
  40. Minor Site details revised at 1 of 91 sitesv35
  41. Minor Site details revised at 1 of 91 sitesv34
  42. Minor Site details revised at 2 of 91 sitesv33
  43. Minor Site details revised at 1 of 91 sitesv32
  44. Minor Site details revised at 2 of 91 sitesv31
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)
Timeframe: Baseline and Week 8

Secondary (3)

Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Change From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8

Arms and interventions

TroriluzoleExperimental

Participants received troriluzole 200 milligrams (mg) (100 mg\*2) capsules orally once daily for the first two weeks and up-titrated to 280 mg (140 mg\*2) capsules orally once daily for the next eight weeks, in the double-blind randomization phase.

PlaceboPlacebo comparator

Participants received placebo-matched to troriluzole capsules orally once daily for 10 weeks of the double-blind randomization phase.

Drugs: Troriluzole, Placebo

Sites

73 sites in 1 country